# The Randomized OPTIMAL-ACT Trial

Study · id `cardio:ct-nct03772613` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03772613](<https://clinicaltrials.gov/study/NCT03772613>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03772613

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

## Technical summary

Registry record NCT03772613. Randomized; double masking; primary purpose treatment. Start 2019-02-08 (actual); primary completion 2021-10-25 (actual). Results posted on 2023-04-04.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 180 participants (enrolled count; ClinicalTrials.gov record NCT03772613, source copy `cardio:ctgov-nct03772613-2023-04-04`, retrieved 2026-10-26)
- Started: 2019-02-08 (actual) (ClinicalTrials.gov record NCT03772613, source copy `cardio:ctgov-nct03772613-2023-04-04`, retrieved 2026-10-26)
- Primary completion: 2021-10-25 (actual) (ClinicalTrials.gov record NCT03772613, source copy `cardio:ctgov-nct03772613-2023-04-04`, retrieved 2026-10-26)
- Completion: 2021-10-25 (actual) (ClinicalTrials.gov record NCT03772613, source copy `cardio:ctgov-nct03772613-2023-04-04`, retrieved 2026-10-26)
- Results first posted: 2023-04-04 (ClinicalTrials.gov record NCT03772613, source copy `cardio:ctgov-nct03772613-2023-04-04`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03772613, source copy `cardio:ctgov-nct03772613-2023-04-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03772613-2023-04-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Randomized OPTIMAL-ACT Trial
- Condition: Coronary Artery Disease
- Condition: Ischemic Heart Disease
- Condition: Anticoagulant-induced Bleeding
- Condition: Coronary Syndrome
- Intervention (Drug): Unfractionated heparin
- Lead sponsor: Mayo Clinic
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Unstable angina (`cardio:unstable-angina`)
- Registry intervention name matches this record: Heparins and low-molecular-weight heparins (`cardio:heparins-and-low-molecular-weight-heparins`)
- Registry intervention is a member of this class by a sourced record link: Anticoagulants (`cardio:anticoagulants`)
- Registry lists this organization as the lead sponsor: Mayo Clinic (`cardio:org-mayo-clinic`)

## Provenance

Content hash: 7365b8b6c84472ce4521e2ec13caa18f13d04dac372139fda6da1ca0a4f5390c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
